Related Experiment Video

Updated: May 7, 2026

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
08:30

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

Low omentin-1 levels are related with clinical and metabolic parameters in obese children

G Catli1, A Anik, A Abaci

  • 1Faculty of Medicine, Department of Pediatric Endocrinology, Dokuz Eylul University, İzmir, Turkey.

Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association
|October 3, 2013
PubMed

Insights

Serum omentin 1 levels are lower in obese children and correlate negatively with obesity markers. Lower levels may indicate metabolic dysfunction and insulin resistance in pediatric obesity.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Syndrome
  • Adipokines Research

Background:

  • Childhood obesity is a growing epidemic linked to metabolic disturbances.
  • Omentin 1, an adipokine, has potential roles in metabolic health.
  • Its association with obesity and metabolic parameters in children requires further investigation.

Purpose of the Study:

  • To evaluate serum omentin 1 levels in obese children.
  • To determine the relationship between omentin 1 and anthropometric/metabolic parameters.
  • To explore omentin 1's role in childhood obesity and related metabolic issues.

Main Methods:

  • Cross-sectional study comparing 49 obese children with 30 healthy controls.
  • Measurements included anthropometrics (BMI, WC), blood pressure, and metabolic markers (glucose, insulin, lipids).
  • Serum omentin 1 levels were quantified and correlated with clinical parameters.

Main Results:

  • Obese children exhibited higher BMI, insulin resistance (HOMA-IR), and triglycerides, but lower omentin 1 levels than controls.
  • Omentin 1 levels showed negative correlations with BMI, WC, insulin, and HOMA-IR.
  • A trend of lower omentin 1 in insulin-resistant obese children was observed, though not statistically significant.

Conclusions:

  • Serum omentin 1 is lower in obese children and inversely associated with key obesity and metabolic indicators.
  • Omentin 1 may serve as a biomarker for metabolic dysfunction in pediatric obesity.
  • Larger studies are needed to confirm the link between omentin 1 and insulin resistance in this population.

More Related Videos

Mechanism of Regulation of Adipocyte Numbers in Adult Organisms Through Differentiation and Apoptosis Homeostasis08:34

Mechanism of Regulation of Adipocyte Numbers in Adult Organisms Through Differentiation and Apoptosis Homeostasis

Published on: June 3, 2016

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Metabolic States of the Body: Fasting and Starvation01:24

Metabolic States of the Body: Fasting and Starvation

During the initial hours of fasting, the body uses up its glycogen stores as an energy source. Once these glycogen reserves are depleted, the body begins breaking down stored triglycerides and structural proteins. During this stage, glycerol becomes a key substrate for gluconeogenesis, while free fatty acids undergo beta-oxidation to provide energy for tissues, such as skeletal muscle. In the fasting state, the body spares protein breakdown as much as possible to conserve muscle and structural...